Ned Sharpless weighs in on gene therapy pricing debate, suggesting 'the messaging got lost'
PHILADELPHIA — You know the drug pricing debate has reached a new height when the acting FDA commissioner starts to chime in on a public forum.
In response to a question on gene therapies posed during a fireside chat at the annual BIO convention, Ned Sharpless acknowledged the importance of discussing cost — though it doesn’t fall under the FDA’s purview — but said he’s “a little disappointed” in the coverage of the recent approval of Novartis’ spinal muscular atrophy treatment, Zolgensma. The treatment was priced at $2.12 million spread out over a 5-year installment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.